Highest-materiality recent filing
Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock
Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.
CWRU terminates Mosaic's CPMV license for lead candidate MIE-101 over ~$407K unpaid IP fees
Effective March 22, 2024, CWRU terminated the exclusive worldwide license agreement due to financial default.
Mosaic ImmunoEngineering receives $300k for preferred shares; stock moving to OTC Pink
Redeemed remaining 910k Series A Preferred shares for $300k lump sum ($0.33/share), received June 22, 2023.
Mosaic enters redemption agreement for $840K in Series A Preferred; initial $336K received
Holocom to redeem 2.1M Series A Preferred shares for $840K total; initial payment of $336K due July 11, 2022.
Licensed technology covers cowpea mosaic virus (CPMV)-based oncology treatments for human and companion animal cancers.
On July 23, 2024, Mr. Carlton Johnson notified the Board of Directors (the “Board”) of Mosaic ImmunoEngineering, Inc. (the “Company”) of his resignation from the Board effective immediately.
Mr. Paul Lytle, EVP, Chief Financial Officer of the Company, agreed to amend Mr. Lytle’s employment terms from full time status to part time status, not to exceed eight (8) hours per month effective June 1, 2024
Mosaic ImmunoEngineering, Inc. (the “Company”) is deeply saddened to announce that director Ms. Gloria Felcyn passed away on April 17, 2024.
On May 2, 2023, Nicole Steinmetz, Ph.D., advised the board of directors of Mosaic ImmunoEngineering, Inc. (the “Company”) of her intention to resign as a member of the board of directors and acting Chief Scientific Officer effective immediately.
Max materiality 0.85 · Median 0.55 · Most common event other_material